AR082620A1 - Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 - Google Patents
Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2Info
- Publication number
- AR082620A1 AR082620A1 ARP110102907A ARP110102907A AR082620A1 AR 082620 A1 AR082620 A1 AR 082620A1 AR P110102907 A ARP110102907 A AR P110102907A AR P110102907 A ARP110102907 A AR P110102907A AR 082620 A1 AR082620 A1 AR 082620A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- phenyl
- amino
- inhibition
- Prior art date
Links
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 title abstract 2
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- -1 Quinolyl amine compound Chemical class 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuesto de quinolil amina de acuerdo con la fórmula (1) en la que R1 es H, -SO2-alquilo C1-4, -CO-alquilo C1-4, o alquilo C1-4; R2 es -SRa, -SORa, o -SO2Ra, en los que Ra es alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, arilo, o heteroarilo, en los que dicho alquilo C1-6 está opcionalmente sustituido por uno o dos grupos cada uno independientemente seleccionado de ciano, hidroxilo, alcoxi C1-6, alcoxi C1-6-alcoxi C2-6, -CO2H, -CO2-alquilo C1-4, -SO2-alquilo C1-4, cicloalquilo C3-7, fenilo, heteroarilo de 5 - 6 miembros, heteroarilo de 9 - 10 miembros, heterocicloalquilo de 4 - 7 miembros y (fenil)(alquil C1-4)amino-, en los que dicho cicloalquilo C3-7, fenilo, (fenil)(alquil C1-4)amino-, heteroarilo de 5 - 6 miembros, heteroarilo de 9 - 10 miembros o heterocicloalquilo de 4 - 7 miembros están opcionalmente sustituidos por 1 - 3 grupos cada uno independientemente seleccionado de halógeno, -CF3, hidroxilo, amino, alquil C1-4amino-, alquil C1-4-alquil C1-4amino-, alquilo C1-4, fenil-alquil C1-4-, hidroxi-alquilo C1-4 y alcoxi C1-4, dicho cicloalquilo C3-7 o heterocicloalquilo de 4 - 7 miembros está opcionalmente sustituido por 1 - 3 grupos cada uno independientemente seleccionado de halógeno, -CF3, hidroxilo, amino, alquil C1-4amino-, alquil C1-4-alquil C1-4amino-, alquilo C1-4, fenil-alquil C1-4-, hidroxi-alquil C1-4-, oxo y alcoxi C1-4, y dicho arilo o heteroarilo está opcionalmente sustituido por 1 - 3 grupos cada uno independientemente seleccionado de halógeno, -CF3, hidroxilo, amino, alquil C1-4amino-, alquil C1-4-alquil C1-4amino-, alquilo C1-4, fenil-alquil C1-4-, hidroxi-alquil C1-4- y alcoxi C1-4; R3 es metilo, hidroximetilo, trifluorometilo, carboxi, o -CO2-alquilo C1-4; R4 es H, metilo, hidroximetilo, trifluorometilo, carboxi, o -CO2-alquilo C1-4; R5 es H o alquilo C1-3; o una sal o hidrato del mismo. Composición farmacéutica que lo comprende y su uso para preparar un medicamento útil para tratar una enfermedad mediada por la inhibición de la quinasa RIP2. Compuestos útiles para el tratamiento de enfermedades autoinmunes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37234210P | 2010-08-10 | 2010-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082620A1 true AR082620A1 (es) | 2012-12-19 |
Family
ID=45510458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102907A AR082620A1 (es) | 2010-08-10 | 2011-08-10 | Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20120041024A1 (es) |
| EP (1) | EP2603218B1 (es) |
| JP (1) | JP2013533316A (es) |
| AR (1) | AR082620A1 (es) |
| TW (1) | TW201245177A (es) |
| UY (1) | UY33549A (es) |
| WO (1) | WO2012021580A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013022307A2 (pt) * | 2011-03-04 | 2020-09-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | aminoquinolinas como inibidores de quinase |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TWI628178B (zh) * | 2012-08-03 | 2018-07-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑的胺基-喹啉 |
| TWI609011B (zh) * | 2012-08-03 | 2017-12-21 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑的胺基－喹啉 |
| AR092530A1 (es) * | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TWI630203B (zh) | 2013-02-21 | 2018-07-21 | 葛蘭素史克智慧財產發展有限公司 | 做為激酶抑制劑的喹唑啉類 |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016333987A1 (en) | 2015-10-05 | 2018-05-10 | Ny State Psychiatric Institute | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies |
| EP3445759A1 (en) | 2016-04-20 | 2019-02-27 | GlaxoSmithKline Intellectual Property Development Ltd | Conjugates comprising ripk2 inhibitors |
| WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
| WO2020094613A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nod2 inhibitors for the treatment of hereditary periodic fevers |
| CN114014890A (zh) * | 2021-03-12 | 2022-02-08 | 爱科诺生物医药(香港)有限公司 | 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用 |
| WO2025078493A1 (en) | 2023-10-11 | 2025-04-17 | Institut National de la Santé et de la Recherche Médicale | Local administration of ripk2 inhibitors for the curative treatment of allergic asthma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998005647A1 (en) * | 1996-08-01 | 1998-02-12 | Dow Agrosciences Llc | Quinolinium derivatives having fungicidal activity |
| CN1252054C (zh) * | 1996-09-25 | 2006-04-19 | 曾尼卡有限公司 | 抑制生长因子的作用的喹啉衍生物 |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US20030004174A9 (en) * | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| SE0101675D0 (sv) * | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| MX2009004059A (es) * | 2006-10-23 | 2009-04-27 | Sgx Pharmaceuticals Inc | Triazoles biciclicos como moduladores de proteina cinasa. |
| AR092530A1 (es) * | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
-
2011
- 2011-08-08 UY UY0001033549A patent/UY33549A/es unknown
- 2011-08-10 EP EP11816959.8A patent/EP2603218B1/en not_active Not-in-force
- 2011-08-10 US US13/206,706 patent/US20120041024A1/en not_active Abandoned
- 2011-08-10 AR ARP110102907A patent/AR082620A1/es not_active Application Discontinuation
- 2011-08-10 WO PCT/US2011/047183 patent/WO2012021580A1/en not_active Ceased
- 2011-08-10 JP JP2013524193A patent/JP2013533316A/ja not_active Ceased
- 2011-08-10 TW TW100128463A patent/TW201245177A/zh unknown
-
2014
- 2014-05-21 US US14/283,352 patent/US20140256949A1/en not_active Abandoned
-
2015
- 2015-11-05 US US14/933,201 patent/US20160060249A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160060249A1 (en) | 2016-03-03 |
| EP2603218A1 (en) | 2013-06-19 |
| WO2012021580A1 (en) | 2012-02-16 |
| US20140256949A1 (en) | 2014-09-11 |
| EP2603218A4 (en) | 2014-01-15 |
| JP2013533316A (ja) | 2013-08-22 |
| UY33549A (es) | 2012-01-31 |
| EP2603218B1 (en) | 2016-03-02 |
| US20120041024A1 (en) | 2012-02-16 |
| TW201245177A (en) | 2012-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082620A1 (es) | Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| CY1120703T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| EA201692506A2 (ru) | Ингибиторы репликации вирусов гриппа | |
| MX2020012695A (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
| BR112015008480A2 (pt) | compostos de benzeno substituído | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| BR112019008415A2 (pt) | composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
| BR112015029455A8 (pt) | compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer | |
| BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
| BR112015020787A2 (pt) | inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |